Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

Do you check IgA levels before starting IVIG for other autoimmune conditions?

2
3 Answers

Mednet Member
Mednet Member
Rheumatology · University of California (San Francisco) School of Medicine

Whereas it is not mandatory to check IgA levels before starting IVIG, it is prudent to do so in non-urgent situations since the patients with IgA deficiency, especially those who have developed anti-IgA antibodies, are at an increased risk of severe hypersensitivity or anaphylactic reactions from IV...

Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?

2
4 Answers

Mednet Member
Mednet Member
Pulmonology · University of Alabama Birmingham

If the predominant findings on CT were ground glass opacities and/or nodules without any evidence of fibrosis on CT, I would not start with an antifibrotic and, instead, would start with immunosuppression as a first-line agent. Based on the American College of Rheumatology (ACR) and American Thoraci...

In patients without Raynaud’s, how frequently do you perform nailfold examination during the initial clinical assessment?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Mayo Clinic

Doing a simple bedside nailfold examination (inspection with the naked eye, otoscope/dermatoscope) is important to do at least once, as part of the general physical examination on all patients, irrespective of Raynaud’s. It might not add value or need to be repeated routinely in patients without Ray...

Over what timeline do you typically try to escalate your LN patients to triple therapy?

4 Answers

Mednet Member
Mednet Member
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

The new recommendation is "Early Quadruple Therapy" per the 2025 EULAR Lupus Nephritis Guidelines announced during a presentation at EULAR 2025 by Dr. Dimitrios Boumpos.Kudos to EULAR! They recommend this to: increase remission rates reduce the need for steroids with these steroid-sparing agents red...

What treatment strategies would you utilize in a patient with newly diagnosed HLA-B27+ axial spondyloarthritis (with active and chronic sacroiliitis on MRI) and recent diagnosis of MS that is well-controlled MS ocrelizumab given the need to avoid TNF inhibitors?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Columbia University - New York Presbyterian Hospital

This is a very challenging scenario. On one hand, TNFi are generally unsafe for MS due to demyelination risk, and on the other hand, anti-CD20 therapies for MS are linked to new AxSpA, but B-cell depletion might also benefit AxSpA. Thus, management requires specialized care in balancing both disease...

Would you proceed with renal transplant in a patient with lupus nephritis who has progressed to ESRD and is clinically stable, but has persistently elevated dsDNA and low complements despite appropriate doses of hydroxychloroquine and mycophenolate?

7
4 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama Birmingham

Short answer: Yes—if the patient’s clinical lupus is quiescent for at least 6 months, it is reasonable to proceed with kidney transplantation even in the presence of persistent serologic activity (e.g., low complement, elevated anti-dsDNA).Why this matters: Transplant > Dialysis: Patients with LN-ES...

Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?

2 Answers

Mednet Member
Mednet Member
Pulmonology · E Town Lung Specialists Psc

Yes, I would consider early starting biologics for infiltrative EGPA.

Are there any successful disease modifying therapy for diffuse idiopathic skeletal hyperostosis (DISH)?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · Stanford University

Therapy for DISH is largely supportive: PT, NSAIDs/pain relievers, and control of contributing metabolic conditions, nutrition, exercise, and lifestyle changes; when necessary surgical interventions such as surgical resection of osteophytes and spinal fusion are required.Clinical research in DISH is...

How do you approach DMARD therapy in a patient with lupus and recurrent pericarditis?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

Both asymptomatic pericardial effusions and symptomatic pericarditis are common in systemic lupus erythematosus (SLE) patients. I will limit my answer to symptomatic pericarditis per the question.The first thing to be sure of is that the symptoms are truly due to pericarditis. The full differential ...

Does treatment with hydroxychloroquine increase the risk of hypertension or exacerbate pre-existing hypertension?

2 Answers

Mednet Member
Mednet Member
Rheumatology · MUSC Health

The answer to this question is that it depends. A number of studies have reported improvement of hypertension with hydroxychloroquine. A large population study suggested there is a subpopulation of patients that may experience an increase in blood pressure on hydroxychloroquine, primarily women over...